Knight Therapeutics (GUD) Competitors

Knight Therapeutics logo
C$11.92 -0.14 (-1.16%)
As of 11/16/2026 04:00 PM Eastern

GUD vs. BHC, CRON, MJN, CARA, and DHT.UN

Should you buy Knight Therapeutics stock or one of its competitors? Knight Therapeutics's main competitors and comparable companies include Bausch Health Companies (BHC), Cronos Group (CRON), Cronos Group (MJN), Cara Operations (CARA), and DRI Healthcare Trust (DHT.UN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Knight Therapeutics compare to Bausch Health Companies?

Knight Therapeutics (TSE:GUD) and Bausch Health Companies (TSE:BHC) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

21.1% of Knight Therapeutics shares are held by institutional investors. Comparatively, 9.7% of Bausch Health Companies shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Comparatively, 11.3% of Bausch Health Companies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Knight Therapeutics has a net margin of 2.84% compared to Bausch Health Companies' net margin of -7.43%. Bausch Health Companies' return on equity of 57.67% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics2.84% 2.03% 0.51%
Bausch Health Companies -7.43%57.67%4.16%

Knight Therapeutics currently has a consensus price target of C$9.50, suggesting a potential downside of 20.30%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Bausch Health Companies
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Knight Therapeutics and Knight Therapeutics both had 1 articles in the media. Knight Therapeutics' average media sentiment score of 0.72 beat Bausch Health Companies' score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Knight Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bausch Health Companies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Knight Therapeutics has a beta of -0.507722, indicating that its stock price is 151% less volatile than the broader market. Comparatively, Bausch Health Companies has a beta of 0.734205, indicating that its stock price is 27% less volatile than the broader market.

Knight Therapeutics has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$563.45M2.08-C$30.73MC$0.1674.50
Bausch Health CompaniesC$11.11B0.41-C$125.65M-C$2.26N/A

Summary

Knight Therapeutics beats Bausch Health Companies on 11 of the 15 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Cronos Group (TSE:CRON) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Cronos Group has a net margin of 27.93% compared to Knight Therapeutics' net margin of 2.84%. Cronos Group's return on equity of 5.35% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group27.93% 5.35% -3.73%
Knight Therapeutics 2.84%2.03%0.51%

4.6% of Cronos Group shares are owned by institutional investors. Comparatively, 21.1% of Knight Therapeutics shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Knight Therapeutics has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$206.20M8.34-C$32.78MC$0.1629.31
Knight TherapeuticsC$563.45M2.08-C$30.73MC$0.1674.50

In the previous week, Cronos Group and Cronos Group both had 1 articles in the media. Knight Therapeutics' average media sentiment score of 0.72 beat Cronos Group's score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cronos Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Knight Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cronos Group currently has a consensus price target of C$4.92, suggesting a potential upside of 4.83%. Knight Therapeutics has a consensus price target of C$9.50, suggesting a potential downside of 20.30%. Given Cronos Group's higher possible upside, research analysts plainly believe Cronos Group is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cronos Group has a beta of 1.196561, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.507722, suggesting that its share price is 151% less volatile than the broader market.

Summary

Cronos Group beats Knight Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Knight Therapeutics (TSE:GUD) and Cronos Group (CVE:MJN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

In the previous week, Knight Therapeutics had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Cronos Group. Knight Therapeutics' average media sentiment score of 0.72 beat Cronos Group's score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Knight Therapeutics Positive
Cronos Group Neutral

21.1% of Knight Therapeutics shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cronos Group has lower revenue, but higher earnings than Knight Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$563.45M2.08-C$30.73MC$0.1674.50
Cronos GroupN/AN/AN/AN/AN/A

Knight Therapeutics currently has a consensus target price of C$9.50, suggesting a potential downside of 20.30%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Knight Therapeutics has a net margin of 2.84% compared to Cronos Group's net margin of 0.00%. Knight Therapeutics' return on equity of 2.03% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics2.84% 2.03% 0.51%
Cronos Group N/A N/A N/A

Summary

Knight Therapeutics beats Cronos Group on 11 of the 11 factors compared between the two stocks.

How does Knight Therapeutics compare to Cara Operations?

Cara Operations (TSE:CARA) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Knight Therapeutics has a consensus price target of C$9.50, indicating a potential downside of 20.30%. Given Cara Operations' higher possible upside, research analysts clearly believe Cara Operations is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Operations
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

21.1% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Knight Therapeutics had 1 more articles in the media than Cara Operations. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Cara Operations. Knight Therapeutics' average media sentiment score of 0.72 beat Cara Operations' score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cara Operations Neutral
Knight Therapeutics Positive

Knight Therapeutics has a net margin of 2.84% compared to Cara Operations' net margin of 0.00%. Knight Therapeutics' return on equity of 2.03% beat Cara Operations' return on equity.

Company Net Margins Return on Equity Return on Assets
Cara OperationsN/A N/A N/A
Knight Therapeutics 2.84%2.03%0.51%

Cara Operations has higher earnings, but lower revenue than Knight Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara OperationsN/AN/AN/AN/AN/A
Knight TherapeuticsC$563.45M2.08-C$30.73MC$0.1674.50

Summary

Knight Therapeutics beats Cara Operations on 10 of the 11 factors compared between the two stocks.

How does Knight Therapeutics compare to DRI Healthcare Trust?

Knight Therapeutics (TSE:GUD) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

21.1% of Knight Therapeutics shares are held by institutional investors. Comparatively, 0.3% of DRI Healthcare Trust shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Knight Therapeutics has a beta of -0.507722, indicating that its share price is 151% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.087008, indicating that its share price is 91% less volatile than the broader market.

Knight Therapeutics currently has a consensus price target of C$9.50, suggesting a potential downside of 20.30%. DRI Healthcare Trust has a consensus price target of C$25.60, suggesting a potential upside of 32.30%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts plainly believe DRI Healthcare Trust is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

In the previous week, Knight Therapeutics had 1 more articles in the media than DRI Healthcare Trust. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for DRI Healthcare Trust. Knight Therapeutics' average media sentiment score of 0.72 beat DRI Healthcare Trust's score of 0.50 indicating that Knight Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Knight Therapeutics Positive
DRI Healthcare Trust Positive

DRI Healthcare Trust has lower revenue, but higher earnings than Knight Therapeutics. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$563.45M2.08-C$30.73MC$0.1674.50
DRI Healthcare TrustC$172.74M6.15C$9.73MC$1.0817.92

DRI Healthcare Trust has a net margin of 5.02% compared to Knight Therapeutics' net margin of 2.84%. DRI Healthcare Trust's return on equity of 2.06% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics2.84% 2.03% 0.51%
DRI Healthcare Trust 5.02%2.06%4.22%

Summary

DRI Healthcare Trust beats Knight Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Knight Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GUD vs. The Competition

MetricKnight TherapeuticsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$1.17BC$13.69BC$7.83BC$12.83B
Dividend YieldN/A2.58%2.46%4.65%
P/E Ratio74.5026.7133.7829.78
Price / Sales2.087.318.583.81
Price / Cash3.8515.7421.9334.92
Price / Book1.475.144.403.42
Net Income-C$30.73MC$2.88BC$3.52BC$299.09M
7 Day Performance-0.50%-3.31%-4.48%-2.27%
1 Month Performance7.97%-3.80%-3.53%-3.40%
1 Year Performance94.45%-7.24%0.12%13.64%

Knight Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GUD
Knight Therapeutics
0.6557 of 5 stars
C$11.92
-1.2%
C$9.50
-20.3%
+94.1%C$1.17BC$563.45M74.50830
BHC
Bausch Health Companies
0.4409 of 5 stars
C$11.29
-3.3%
N/A+36.6%C$4.23BC$11.11BN/A20,300
CRON
Cronos Group
0.9441 of 5 stars
C$5.23
+6.1%
C$4.92
-6.0%
+35.9%C$1.93BC$179.09M27.53610
MJN
Cronos Group
N/AC$12.15
-1.9%
N/A+0.0%C$1.73BN/AN/A7,600
CARA
Cara Operations
N/AN/AN/AN/AC$1.62BN/AN/A80

Related Companies and Tools


This page (TSE:GUD) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners